Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
- PMID: 31575503
- DOI: 10.1016/S1470-2045(19)30616-3
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Abstract
Background: Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains immune cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the immune cells and bone marrow from chemotherapy-induced damage, trilaciclib has the potential to optimise antitumour activity while minimising myelotoxicity. We report safety and activity data for trilaciclib plus gemcitabine and carboplatin chemotherapy in patients with metastatic triple-negative breast cancer.
Methods: In this randomised, open-label, multicentre, phase 2 study, adult patients (aged ≥18 years) with evaluable, biopsy-confirmed, locally recurrent or metastatic triple-negative breast cancer who had no more than two previous lines of chemotherapy were recruited from 26 sites in the USA, three in Serbia, two in North Macedonia, one in Croatia, and one in Bulgaria; sites were academic and community hospitals. Availability of diagnostic samples of tumour tissue confirming triple-negative breast cancer was a prerequisite for enrolment. Eligible patients were randomly assigned (1:1:1) by an interactive web-response system, stratified by number of previous lines of systemic therapy and the presence of liver metastases, to receive intravenous gemcitabine 1000 mg/m2 and intravenous carboplatin (area under the concentration-time curve 2 μg × h/mL) on days 1 and 8 (group 1), gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2), or gemcitabine and carboplatin on days 2 and 9 plus trilaciclib on days 1, 2, 8, and 9 (group 3) of 21-day cycles. Patients continued treatment until disease progression, unacceptable toxicity, withdrawal of consent, or discontinuation by the investigator. The primary objective was to assess the safety and tolerability of combining trilaciclib with gemcitabine and carboplatin chemotherapy. The primary endpoints were duration of severe neutropenia during cycle 1 and the occurrence of severe neutropenia during the treatment period. Overall survival was included as a key secondary endpoint. Analyses were in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with EudraCT, 2016-004466-26, and ClinicalTrials.gov, NCT02978716, and is ongoing but closed to accrual.
Findings: Between Feb 7, 2017, and May 15, 2018, 142 patients were assessed for eligibility and 102 were randomly assigned to group 1 (n=34), group 2 (n=33), or group 3 (n=35). Of all patients, 38 (37%) had received one or two lines of previous chemotherapy in the metastatic setting. Median follow-up was 8·4 months (IQR 3·8-13·6) for group 1, 12·7 months (5·5-17·4) for group 2, and 12·9 months (6·7-16·8) for group 3. Data cutoff for myelosuppression endpoints was July 30, 2018, and for antitumour activity endpoints was May 17, 2019. During cycle 1, mean duration of severe neutropenia was 0·8 day (SD 2·4) in group 1, 1·5 days (3·5) in group 2, and 1·0 day (2·6) in group 3 (group 3 vs group 1 one-sided adjusted p=0·70). Severe neutropenia occurred in nine (26%) of 34 patients in group 1, 12 (36%) of 33 patients in group 2, and eight (23%) of 35 patients in group 3 (p=0·70). Overall survival was 12·6 months (IQR 5·8-15·6) in group 1, 20·1 months (9·4-not reached) in group 2, and 17·8 months (8·8-not reached) in group 3 (group 3 vs group 1 two-sided p=0·0023). The most common treatment-emergent adverse events were anaemia (22 [73%] of 34), neutropenia (21 [70%]), and thrombocytopenia (18 [60%]) in group 1; neutropenia (27 [82%] of 33), thrombocytopenia (18 [55%]) and anaemia (17 [52%]) in group 2; and neutropenia (23 [66%] of 35), thrombocytopenia (22 [63%]), and nausea (17 [49%]) in group 3. There were no treatment-related deaths.
Interpretation: No significant differences were observed in myelosuppression endpoints with trilaciclib plus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer; however, the regimen was generally well tolerated and overall survival results were encouraging. Further studies of trilaciclib in this setting are warranted.
Funding: G1 Therapeutics.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?Lancet Oncol. 2019 Nov;20(11):1479-1481. doi: 10.1016/S1470-2045(19)30627-8. Epub 2019 Sep 28. Lancet Oncol. 2019. PMID: 31575504 No abstract available.
Similar articles
-
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol. 2015 Apr;16(4):436-46. doi: 10.1016/S1470-2045(15)70064-1. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795409 Clinical Trial.
-
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.
-
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7. Trials. 2015. PMID: 26673577 Free PMC article. Clinical Trial.
-
Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature.Eur J Cancer Care (Engl). 2010 May;19(3):324-8. doi: 10.1111/j.1365-2354.2008.01050.x. Epub 2009 Nov 11. Eur J Cancer Care (Engl). 2010. PMID: 19912300 Review.
-
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.Curr Oncol Rep. 2022 Dec;24(12):1695-1703. doi: 10.1007/s11912-022-01324-x. Epub 2022 Aug 20. Curr Oncol Rep. 2022. PMID: 35986858 Review.
Cited by
-
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.Front Oncol. 2021 Jul 8;11:697908. doi: 10.3389/fonc.2021.697908. eCollection 2021. Front Oncol. 2021. PMID: 34307165 Free PMC article. Review.
-
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.Nat Rev Urol. 2022 May;19(5):305-320. doi: 10.1038/s41585-022-00571-8. Epub 2022 Mar 9. Nat Rev Urol. 2022. PMID: 35264774 Free PMC article. Review.
-
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.Clin Cancer Res. 2022 Feb 15;28(4):629-636. doi: 10.1158/1078-0432.CCR-21-2272. Clin Cancer Res. 2022. PMID: 34887261 Free PMC article. Clinical Trial.
-
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer.Invest New Drugs. 2025 Jun;43(3):728-741. doi: 10.1007/s10637-025-01550-7. Epub 2025 Jun 6. Invest New Drugs. 2025. PMID: 40478388 Free PMC article.
-
Small molecule agents for triple negative breast cancer: Current status and future prospects.Transl Oncol. 2024 Mar;41:101893. doi: 10.1016/j.tranon.2024.101893. Epub 2024 Jan 29. Transl Oncol. 2024. PMID: 38290250 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical